- Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
- Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
- Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
- Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
- Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
- Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
- Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
More ▼
Key statistics
As of last trade Edgewise Therapeutics Inc (EWTX:NSQ) traded at 17.72, -17.96% below its 52-week high of 21.60, set on May 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.96 |
---|---|
High | 18.44 |
Low | 17.66 |
Bid | 17.68 |
Offer | 17.73 |
Previous close | 18.01 |
Average volume | 549.58k |
---|---|
Shares outstanding | 93.41m |
Free float | 93.10m |
P/E (TTM) | -- |
Market cap | 1.60bn USD |
EPS (TTM) | -1.53 USD |
Data delayed at least 15 minutes, as of Jun 06 2024 17:29 BST.
More ▼